App-based symptom tracker aims to boost quality of life for liver cancer patients
NCT ID NCT06938945
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests whether a smartphone app that tracks symptoms can improve quality of life for 500 liver cancer patients receiving immunotherapy. Patients in the intervention group report symptoms weekly via the app, which gives personalized advice and alerts doctors if scores are concerning. The control group receives usual care. The goal is to see if digital monitoring helps patients manage side effects and feel better overall.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
digital symptom monitoring app (behavioral intervention)
What this could lead to
If successful, this could show that a simple app helps liver cancer patients manage symptoms better and improves their quality of life during treatment.
What could go wrong
This is a behavioral intervention, not a drug, so it won't treat the cancer itself. The benefit depends on patients and doctors acting on the alerts, which may not always happen.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China Center for Health Development Studies, Peking University
RECRUITINGHaidian, Beijing Municipality, 100191, China
Contact Phone: •••-•••-•••• Email: •••••@•••••